Castle Biosciences' AdvanceAD-Tx Shows 97.8% Concordance in Atopic Dermatitis Study
CSTL sits 96% above its 52-week low of $14.59.
Summary
A new study shows Castle's AdvanceAD-Tx test led to 97.8% pathway-concordant systemic therapy decisions for atopic dermatitis, nearly doubling the 54.3% baseline. This follows yesterday's Q2 revenue beat and raised guidance, adding a clinical validation catalyst. The data strengthens the test's reimbursement and adoption case in a growing market. No specific upcoming event to watch.
At the time of this announcement, CSTL was trading at $28.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $812.5M. The 52-week trading range was $14.59 to $44.28. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.